Lakefront Biotherapeutics - American Depositary Shares (LKFT)
33.31
-0.08 (-0.24%)
NASDAQ · Last Trade: Nov 22nd, 11:24 AM EST
Detailed Quote
| Previous Close | 33.39 |
|---|---|
| Open | 33.61 |
| Bid | 33.27 |
| Ask | 33.31 |
| Day's Range | 33.25 - 33.85 |
| 52 Week Range | 25.68 - 35.54 |
| Volume | 162,487 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 263,294 |
Chart
News & Press Releases
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) is preparing to expand testing of its autoimmune drug candidate gamgertamig, with executives pointing to clinical data, potential registrational trials and a sizable cash balance as the company moves beyond its former cell therapy fo
Via MarketBeat · November 21, 2026
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines.
Speaking at M
Via MarketBeat · September 21, 2026
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.
By Gilead Sciences, Inc. · Via Business Wire · June 4, 2026
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
Via The Motley Fool · May 23, 2026
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Via The Motley Fool · May 23, 2026
